glp-1 cardiovascular outcomes 2025 news ISPOR 2025: Exploring reasons for discontinuation Beyond GLP1: modulating multiple nutrient-stimulated

Weight Loss Medications Olivera believes that a healthier, more confident life starts with individualized, science-driven treatments not a one-size-fits-all solution

All participants were T2DM patients being treated with a combination of metformin, sodium-glucose co-transporter-2, or sulfonylurea

"The underreported symptoms are leads that came from patients themselves, unprompted, and clinicians could potentially pay attention to them." Lyle Ungar, Professor in CIS and a co-author of the study, says social media can offer insight into concerns patients may not always bring up during medical visits

10.1016/j.gie.2024.01.012 30

In most cases, you can expect some weight loss by week four, says Dr